JP2001501958A - 性的能力障害治療用ピラゾリノン化合物 - Google Patents

性的能力障害治療用ピラゾリノン化合物

Info

Publication number: JP2001501958A
Authority: JP; Japan
Prior art keywords: dihydro; oxo; pyrazol; ethylanilinomethylene; atoms
Prior art date: 1996-10-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP10517987A

Other languages

English (en)

Japanese (ja)

Inventor

アールト、ミハエル

ヨナス、ロハウス

シェリング、ピール

クリスタドラー、マリア

クルクセン、フランツ―ヴェルネル

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Merck Patent GmbH

Original Assignee

Merck Patent GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-10-14

Filing date

1997-10-08

Publication date

2001-02-13

1997-10-08 Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH

2001-02-13 Publication of JP2001501958A publication Critical patent/JP2001501958A/ja

Status Pending legal-status Critical Current

Links

201000001880 Sexual dysfunction Diseases 0.000 title claims abstract description 16
231100000872 sexual dysfunction Toxicity 0.000 title claims abstract description 16
XBYRMPXUBGMOJC-UHFFFAOYSA-N 1,2-dihydropyrazol-3-one Chemical class OC=1C=CNN=1 XBYRMPXUBGMOJC-UHFFFAOYSA-N 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 45
238000002560 therapeutic procedure Methods 0.000 claims abstract description 9
-1 4-methoxycarbonylaminophenyl Chemical group 0.000 claims description 38
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 30
125000003545 alkoxy group Chemical group 0.000 claims description 13
229910052736 halogen Inorganic materials 0.000 claims description 13
150000002367 halogens Chemical class 0.000 claims description 13
125000000217 alkyl group Chemical group 0.000 claims description 12
150000003839 salts Chemical class 0.000 claims description 11
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
125000004432 carbon atom Chemical group C* 0.000 claims description 9
239000003814 drug Substances 0.000 claims description 9
229910052731 fluorine Inorganic materials 0.000 claims description 8
229910052794 bromium Inorganic materials 0.000 claims description 7
229910052801 chlorine Inorganic materials 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 7
238000000034 method Methods 0.000 claims description 7
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
125000001309 chloro group Chemical group Cl* 0.000 claims description 6
125000001153 fluoro group Chemical group F* 0.000 claims description 6
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
229910052740 iodine Inorganic materials 0.000 claims description 6
239000007788 liquid Substances 0.000 claims description 6
125000000896 monocarboxylic acid group Chemical group 0.000 claims description 6
125000002947 alkylene group Chemical group 0.000 claims description 5
229910052739 hydrogen Inorganic materials 0.000 claims description 5
239000000203 mixture Substances 0.000 claims description 4
125000004430 oxygen atom Chemical group O* 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 4
229920006395 saturated elastomer Polymers 0.000 claims description 4
125000004434 sulfur atom Chemical group 0.000 claims description 4
125000003831 tetrazolyl group Chemical group 0.000 claims description 4
238000009472 formulation Methods 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
239000000825 pharmaceutical preparation Substances 0.000 claims description 3
JDEWCXQUEHIOMW-UHFFFAOYSA-N 4-[4-[(2-ethylanilino)methylidene]-3-methyl-5-oxopyrazol-1-yl]benzoic acid Chemical compound CCC1=CC=CC=C1NC=C1C(=O)N(C=2C=CC(=CC=2)C(O)=O)N=C1C JDEWCXQUEHIOMW-UHFFFAOYSA-N 0.000 claims description 2
XTKQOGSBBVWVFQ-UHFFFAOYSA-N 4-[4-[(2-ethylanilino)methylidene]-5-oxo-3-propylpyrazol-1-yl]benzoic acid Chemical compound CCCC1=NN(C=2C=CC(=CC=2)C(O)=O)C(=O)C1=CNC1=CC=CC=C1CC XTKQOGSBBVWVFQ-UHFFFAOYSA-N 0.000 claims description 2
GGBYCKWNPYSSHX-UHFFFAOYSA-N n-[4-[4-[(2-ethylanilino)methylidene]-3-methyl-5-oxopyrazol-1-yl]phenyl]acetamide Chemical compound CCC1=CC=CC=C1NC=C1C(=O)N(C=2C=CC(NC(C)=O)=CC=2)N=C1C GGBYCKWNPYSSHX-UHFFFAOYSA-N 0.000 claims description 2
125000004076 pyridyl group Chemical group 0.000 claims description 2
239000007787 solid Substances 0.000 claims description 2
DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 2
239000004480 active ingredient Substances 0.000 description 15
239000000243 solution Substances 0.000 description 8
239000003826 tablet Substances 0.000 description 7
239000000126 substance Substances 0.000 description 5
150000001408 amides Chemical class 0.000 description 4
ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 3
208000005392 Spasm Diseases 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000012154 double-distilled water Substances 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
239000007921 spray Substances 0.000 description 3
239000000829 suppository Substances 0.000 description 3
WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
239000005711 Benzoic acid Substances 0.000 description 2
208000024172 Cardiovascular disease Diseases 0.000 description 2
206010010904 Convulsion Diseases 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
239000004264 Petrolatum Substances 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
235000010233 benzoic acid Nutrition 0.000 description 2
238000000576 coating method Methods 0.000 description 2
239000003086 colorant Substances 0.000 description 2
230000036461 convulsion Effects 0.000 description 2
210000005226 corpus cavernosum Anatomy 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000000694 effects Effects 0.000 description 2
201000001881 impotence Diseases 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
239000008101 lactose Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000005259 measurement Methods 0.000 description 2
239000002674 ointment Substances 0.000 description 2
229940066842 petrolatum Drugs 0.000 description 2
235000019271 petrolatum Nutrition 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
229960001802 phenylephrine Drugs 0.000 description 2
229920001592 potato starch Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical class O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
FXTSJTAACSNGPU-UHFFFAOYSA-N 1-butoxy-3-ethoxy-4-methoxy-2-propoxybenzene Chemical compound COC1=C(C(=C(C=C1)OCCCC)OCCC)OCC FXTSJTAACSNGPU-UHFFFAOYSA-N 0.000 description 1
PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
NRKYWOKHZRQRJR-UHFFFAOYSA-N 2,2,2-trifluoroacetamide Chemical compound NC(=O)C(F)(F)F NRKYWOKHZRQRJR-UHFFFAOYSA-N 0.000 description 1
CTONXMXIVHRAIJ-UHFFFAOYSA-N 2-(4-bromophenyl)-4-[(2-ethylanilino)methylidene]-5-propylpyrazol-3-one Chemical compound CCCC1=NN(C=2C=CC(Br)=CC=2)C(=O)C1=CNC1=CC=CC=C1CC CTONXMXIVHRAIJ-UHFFFAOYSA-N 0.000 description 1
OKSZKDZGYVHHFU-UHFFFAOYSA-N 2-(4-chlorophenyl)-4-[(2-ethylanilino)methylidene]-5-methylpyrazol-3-one Chemical compound CCC1=CC=CC=C1NC=C1C(=O)N(C=2C=CC(Cl)=CC=2)N=C1C OKSZKDZGYVHHFU-UHFFFAOYSA-N 0.000 description 1
DUOFQJHMHMNWFY-UHFFFAOYSA-N 3-[4-[(2-ethylanilino)methylidene]-3-methyl-5-oxopyrazol-1-yl]benzonitrile Chemical compound CCC1=CC=CC=C1NC=C1C(=O)N(C=2C=C(C=CC=2)C#N)N=C1C DUOFQJHMHMNWFY-UHFFFAOYSA-N 0.000 description 1
WHCJYLBESJEITM-UHFFFAOYSA-N 3-[4-[(2-ethylanilino)methylidene]-5-oxo-3-propylpyrazol-1-yl]benzenesulfonic acid Chemical compound CCCC1=NN(C=2C=C(C=CC=2)S(O)(=O)=O)C(=O)C1=CNC1=CC=CC=C1CC WHCJYLBESJEITM-UHFFFAOYSA-N 0.000 description 1
XBFAHZOFAVJHQR-UHFFFAOYSA-N 3-[4-[(2-ethylanilino)methylidene]-5-oxo-3-propylpyrazol-1-yl]benzoic acid Chemical compound CCCC1=NN(C=2C=C(C=CC=2)C(O)=O)C(=O)C1=CNC1=CC=CC=C1CC XBFAHZOFAVJHQR-UHFFFAOYSA-N 0.000 description 1
RHMFDBSVXUUHDE-UHFFFAOYSA-N 4-[(2-butoxyanilino)methylidene]-5-methyl-2-(4-morpholin-4-ylsulfonylphenyl)pyrazol-3-one Chemical compound CCCCOC1=CC=CC=C1NC=C1C(=O)N(C=2C=CC(=CC=2)S(=O)(=O)N2CCOCC2)N=C1C RHMFDBSVXUUHDE-UHFFFAOYSA-N 0.000 description 1
CWVBHDWXBKCALE-UHFFFAOYSA-N 4-[(2-ethoxyanilino)methylidene]-5-methyl-2-(4-morpholin-4-ylsulfonylphenyl)pyrazol-3-one Chemical compound CCOC1=CC=CC=C1NC=C1C(=O)N(C=2C=CC(=CC=2)S(=O)(=O)N2CCOCC2)N=C1C CWVBHDWXBKCALE-UHFFFAOYSA-N 0.000 description 1
WNEAAYGROGCTLU-UHFFFAOYSA-N 4-[(2-ethylanilino)methylidene]-2-(4-nitrophenyl)-5-propylpyrazol-3-one Chemical compound CCCC1=NN(C=2C=CC(=CC=2)[N+]([O-])=O)C(=O)C1=CNC1=CC=CC=C1CC WNEAAYGROGCTLU-UHFFFAOYSA-N 0.000 description 1
KECMBRCFXSRBLZ-UHFFFAOYSA-N 4-[(2-ethylanilino)methylidene]-2-[(4-methoxyphenyl)methyl]-5-propylpyrazol-3-one Chemical compound O=C1C(=CNC=2C(=CC=CC=2)CC)C(CCC)=NN1CC1=CC=C(OC)C=C1 KECMBRCFXSRBLZ-UHFFFAOYSA-N 0.000 description 1
LXLTXXYGSKVJRR-UHFFFAOYSA-N 4-[(2-ethylanilino)methylidene]-5-methyl-2-(4-morpholin-4-ylsulfonylphenyl)pyrazol-3-one Chemical compound CCC1=CC=CC=C1NC=C1C(=O)N(C=2C=CC(=CC=2)S(=O)(=O)N2CCOCC2)N=C1C LXLTXXYGSKVJRR-UHFFFAOYSA-N 0.000 description 1
CGDWFCAFBGRLCS-UHFFFAOYSA-N 4-[(2-ethylanilino)methylidene]-5-methyl-2-(4-nitrophenyl)pyrazol-3-one Chemical compound CCC1=CC=CC=C1NC=C1C(=O)N(C=2C=CC(=CC=2)[N+]([O-])=O)N=C1C CGDWFCAFBGRLCS-UHFFFAOYSA-N 0.000 description 1
HKCYNIJNRPAVGT-UHFFFAOYSA-N 4-[(2-ethylanilino)methylidene]-5-methyl-2-[3-(2h-tetrazol-5-yl)phenyl]pyrazol-3-one Chemical compound CCC1=CC=CC=C1NC=C1C(=O)N(C=2C=C(C=CC=2)C=2NN=NN=2)N=C1C HKCYNIJNRPAVGT-UHFFFAOYSA-N 0.000 description 1
CAAFMABGGYVWES-UHFFFAOYSA-N 4-[(2-ethylanilino)methylidene]-5-methyl-2-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]pyrazol-3-one Chemical compound CCC1=CC=CC=C1NC=C1C(=O)N(C=2C=CC(=CC=2)S(=O)(=O)N2CCN(C)CC2)N=C1C CAAFMABGGYVWES-UHFFFAOYSA-N 0.000 description 1
GYZMJXUVVIBPEX-UHFFFAOYSA-N 4-[(2-ethylanilino)methylidene]-5-methyl-2-pyridin-2-ylpyrazol-3-one Chemical compound CCC1=CC=CC=C1NC=C1C(=O)N(C=2N=CC=CC=2)N=C1C GYZMJXUVVIBPEX-UHFFFAOYSA-N 0.000 description 1
MBVIGYDIKMKCFH-UHFFFAOYSA-N 4-[(2-ethylanilino)methylidene]-5-propyl-2-[4-(2h-tetrazol-5-yl)phenyl]pyrazol-3-one Chemical compound CCCC1=NN(C=2C=CC(=CC=2)C=2NN=NN=2)C(=O)C1=CNC1=CC=CC=C1CC MBVIGYDIKMKCFH-UHFFFAOYSA-N 0.000 description 1
GPZUQVBPVHIMOM-UHFFFAOYSA-N 4-[(2-ethylanilino)methylidene]-5-propyl-2-pyridin-2-ylpyrazol-3-one Chemical compound CCCC1=NN(C=2N=CC=CC=2)C(=O)C1=CNC1=CC=CC=C1CC GPZUQVBPVHIMOM-UHFFFAOYSA-N 0.000 description 1
ZTAMYGZZLFGRNE-UHFFFAOYSA-N 4-[(2-ethylanilino)methylidene]-5-propyl-2-pyridin-3-ylpyrazol-3-one Chemical compound CCCC1=NN(C=2C=NC=CC=2)C(=O)C1=CNC1=CC=CC=C1CC ZTAMYGZZLFGRNE-UHFFFAOYSA-N 0.000 description 1
XOGHDUZPQVXXAZ-UHFFFAOYSA-N 4-[(2-ethylanilino)methylidene]-5-propyl-2-pyridin-4-ylpyrazol-3-one Chemical compound CCCC1=NN(C=2C=CN=CC=2)C(=O)C1=CNC1=CC=CC=C1CC XOGHDUZPQVXXAZ-UHFFFAOYSA-N 0.000 description 1
SSRMXABWGUTHRT-UHFFFAOYSA-N 4-[3-(2-ethoxy-2-oxoethyl)-4-[(2-ethylanilino)methylidene]-5-oxopyrazol-1-yl]benzoic acid Chemical compound CCOC(=O)CC1=NN(C=2C=CC(=CC=2)C(O)=O)C(=O)C1=CNC1=CC=CC=C1CC SSRMXABWGUTHRT-UHFFFAOYSA-N 0.000 description 1
LNBFWZWULJICRL-UHFFFAOYSA-N 4-[3-methyl-5-oxo-4-[(2-propan-2-ylanilino)methylidene]pyrazol-1-yl]benzoic acid Chemical compound CC(C)C1=CC=CC=C1NC=C1C(=O)N(C=2C=CC(=CC=2)C(O)=O)N=C1C LNBFWZWULJICRL-UHFFFAOYSA-N 0.000 description 1
YFKFRBFVAXZNIP-UHFFFAOYSA-N 4-[3-methyl-5-oxo-4-[[2-(trifluoromethyl)anilino]methylidene]pyrazol-1-yl]benzoic acid Chemical compound CC1=NN(C=2C=CC(=CC=2)C(O)=O)C(=O)C1=CNC1=CC=CC=C1C(F)(F)F YFKFRBFVAXZNIP-UHFFFAOYSA-N 0.000 description 1
JBYFJEHTPNMGSA-UHFFFAOYSA-N 4-[4-[(2-ethylanilino)methylidene]-3-methyl-5-oxopyrazol-1-yl]-n-hexylbenzamide Chemical compound C1=CC(C(=O)NCCCCCC)=CC=C1N(N=C1C)C(=O)C1=CNC1=CC=CC=C1CC JBYFJEHTPNMGSA-UHFFFAOYSA-N 0.000 description 1
YARVSHFFVZFIIT-UHFFFAOYSA-N 4-[4-[(2-ethylanilino)methylidene]-5-oxo-3-propylpyrazol-1-yl]-n-hexylbenzamide Chemical compound C1=CC(C(=O)NCCCCCC)=CC=C1N(N=C1CCC)C(=O)C1=CNC1=CC=CC=C1CC YARVSHFFVZFIIT-UHFFFAOYSA-N 0.000 description 1
KTSSPSPNWZXNHU-UHFFFAOYSA-N 4-[4-[(2-ethylanilino)methylidene]-5-oxo-3-propylpyrazol-1-yl]benzenesulfonic acid Chemical compound CCCC1=NN(C=2C=CC(=CC=2)S(O)(=O)=O)C(=O)C1=CNC1=CC=CC=C1CC KTSSPSPNWZXNHU-UHFFFAOYSA-N 0.000 description 1
KXBILFHHTJTATD-UHFFFAOYSA-N 4-[4-[(2-ethylanilino)methylidene]-5-oxo-3-propylpyrazol-1-yl]benzonitrile Chemical compound CCCC1=NN(C=2C=CC(=CC=2)C#N)C(=O)C1=CNC1=CC=CC=C1CC KXBILFHHTJTATD-UHFFFAOYSA-N 0.000 description 1
MEVIBBPPVUILIO-UHFFFAOYSA-N 5-methyl-2-phenyl-4-[(2-propoxyanilino)methylidene]pyrazol-3-one Chemical compound CCCOC1=CC=CC=C1NC=C1C(=O)N(C=2C=CC=CC=2)N=C1C MEVIBBPPVUILIO-UHFFFAOYSA-N 0.000 description 1
KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
208000010228 Erectile Dysfunction Diseases 0.000 description 1
102000004961 Furin Human genes 0.000 description 1
108090001126 Furin Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010021118 Hypotonia Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
229940124639 Selective inhibitor Drugs 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
239000003708 ampul Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
239000000305 astragalus gummifer gum Substances 0.000 description 1
METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
150000003938 benzyl alcohols Chemical class 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
239000006071 cream Substances 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
239000006196 drop Substances 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
238000001914 filtration Methods 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
235000013773 glyceryl triacetate Nutrition 0.000 description 1
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
239000008187 granular material Substances 0.000 description 1
125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
239000007943 implant Substances 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000002483 medication Methods 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
230000036640 muscle relaxation Effects 0.000 description 1
NUNXGSSNXIYUOT-UHFFFAOYSA-N n,n-diethyl-4-[4-[(2-ethylanilino)methylidene]-3-methyl-5-oxopyrazol-1-yl]benzamide Chemical compound C1=CC(C(=O)N(CC)CC)=CC=C1N(N=C1C)C(=O)C1=CNC1=CC=CC=C1CC NUNXGSSNXIYUOT-UHFFFAOYSA-N 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000018791 negative regulation of catalytic activity Effects 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
DOTPSQVYOBAWPQ-UHFFFAOYSA-N pyrazolo[4,3-d]pyrimidin-3-one Chemical class N1=CN=C2C(=O)N=NC2=C1 DOTPSQVYOBAWPQ-UHFFFAOYSA-N 0.000 description 1
239000002516 radical scavenger Substances 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000008347 soybean phospholipid Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
239000013589 supplement Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 1
229960002622 triacetin Drugs 0.000 description 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Gynecology & Obstetrics (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

JP10517987A 1996-10-14 1997-10-08 性的能力障害治療用ピラゾリノン化合物 Pending JP2001501958A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE19642284A DE19642284A1 (de)	1996-10-14	1996-10-14	Pyrazolinone zur Behandlung von Potenzstörungen
DE19642284.1		1996-10-14
PCT/EP1997/005532 WO1998016224A1 (de)	1996-10-14	1997-10-08	Pyrazolinone zur behandlung von potenzstörungen

Publications (1)

Publication Number	Publication Date
JP2001501958A true JP2001501958A (ja)	2001-02-13

Family

ID=7808669

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP10517987A Pending JP2001501958A (ja)	1996-10-14	1997-10-08	性的能力障害治療用ピラゾリノン化合物

Country Status (14)

Country	Link
EP (1)	EP0930881A1 (es)
JP (1)	JP2001501958A (es)
KR (1)	KR20000049086A (es)
CN (1)	CN1233178A (es)
AR (1)	AR008494A1 (es)
AU (1)	AU4945297A (es)
BR (1)	BR9712307A (es)
CA (1)	CA2268823A1 (es)
DE (1)	DE19642284A1 (es)
HU (1)	HUP0000233A3 (es)
NO (1)	NO991734D0 (es)
PL (1)	PL332821A1 (es)
WO (1)	WO1998016224A1 (es)
ZA (1)	ZA979151B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6410584B1 (en)	1998-01-14	2002-06-25	Cell Pathways, Inc.	Method for inhibiting neoplastic cells with indole derivatives
US6200771B1 (en)	1998-10-15	2001-03-13	Cell Pathways, Inc.	Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6133271A (en) *	1998-11-19	2000-10-17	Cell Pathways, Inc.	Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en)	1998-11-20	2001-02-13	Cell Pathways, Inc.	Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en)	1998-11-23	2002-04-09	Cell Pathways, Inc.	Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6486155B1 (en)	1998-11-24	2002-11-26	Cell Pathways Inc	Method of inhibiting neoplastic cells with isoquinoline derivatives
US6034099A (en) *	1998-11-24	2000-03-07	Cell Pathways, Inc.	Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6077842A (en) *	1998-11-24	2000-06-20	Cell Pathways, Inc.	Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6875575B1 (en)	1998-11-25	2005-04-05	Osi Pharmaceuticals, Inc.	Diagnostic methods for neoplasia
US6020379A (en) *	1999-02-19	2000-02-01	Cell Pathways, Inc.	Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
WO2006034473A2 (en)	2004-09-23	2006-03-30	Reddy Us Therapeutics, Inc.	Novel pyrimidine compounds, process for their preparation and compositions containing them

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9311920D0 (en) *	1993-06-09	1993-07-28	Pfizer Ltd	Therapeutic agents
DE19518082A1 (de) *	1995-05-17	1996-11-21	Merck Patent Gmbh	4(-Arylaminomethylen)-2,4-dihydropyrazol-3-one

1996
- 1996-10-14 DE DE19642284A patent/DE19642284A1/de not_active Withdrawn
1997
- 1997-10-08 AU AU49452/97A patent/AU4945297A/en not_active Abandoned
- 1997-10-08 JP JP10517987A patent/JP2001501958A/ja active Pending
- 1997-10-08 CA CA002268823A patent/CA2268823A1/en not_active Abandoned
- 1997-10-08 PL PL97332821A patent/PL332821A1/xx unknown
- 1997-10-08 HU HU0000233A patent/HUP0000233A3/hu unknown
- 1997-10-08 BR BR9712307-2A patent/BR9712307A/pt not_active Application Discontinuation
- 1997-10-08 WO PCT/EP1997/005532 patent/WO1998016224A1/de not_active Ceased
- 1997-10-08 KR KR1019990703161A patent/KR20000049086A/ko not_active Withdrawn
- 1997-10-08 EP EP97912141A patent/EP0930881A1/de not_active Withdrawn
- 1997-10-08 CN CN97198764A patent/CN1233178A/zh active Pending
- 1997-10-13 ZA ZA9709151A patent/ZA979151B/xx unknown
- 1997-10-14 AR ARP970104715A patent/AR008494A1/es unknown
1999
- 1999-04-13 NO NO991734A patent/NO991734D0/no unknown

Also Published As

Publication number	Publication date
HUP0000233A2 (hu)	2001-04-28
PL332821A1 (en)	1999-10-11
AR008494A1 (es)	2000-01-19
ZA979151B (en)	1998-05-11
KR20000049086A (ko)	2000-07-25
CA2268823A1 (en)	1998-04-23
CN1233178A (zh)	1999-10-27
WO1998016224A1 (de)	1998-04-23
HUP0000233A3 (en)	2001-06-28
AU4945297A (en)	1998-05-11
BR9712307A (pt)	1999-08-31
EP0930881A1 (de)	1999-07-28
NO991734L (no)	1999-04-13
DE19642284A1 (de)	1998-04-16
NO991734D0 (no)	1999-04-13

Publication	Publication Date	Title
TWI235060B (en)	2005-07-01	Pharmaceutical compositions comprising substituted pyrazolyl benzenesulfonamide derivatives for use in treating or preventing an epithelial cell-derived neoplasia
CA2450777A1 (en)	2003-02-20	Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
EP0481675B1 (en)	1995-09-27	Preparation of medicaments for treating asthma using (S)-alpha-fluoromethyl histidine and esters thereof
JP2000515526A (ja)	2000-11-21	Ｍｔｐ阻害剤と他のコレステロール低下薬を組合せて使用する、血清脂質レベルの降下方法
CA2525366A1 (en)	2004-11-25	Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
JP2001501958A (ja)	2001-02-13	性的能力障害治療用ピラゾリノン化合物
JP2012255039A (ja)	2012-12-27	ニコチン性アセチルコリンα７受容体アゴニストの組合せ剤
EA029000B1 (ru)	2018-01-31	КОМБИНАЦИЯ БОРТЕЗОМИДА И Akt-ИНГИБИТОРА ДЛЯ ЛЕЧЕНИЯ МНОЖЕСТВЕННОЙ МИЕЛОМЫ
JPH0667841B2 (ja)	1994-08-31	恐慌障害の軽減剤
JPS63211228A (ja)	1988-09-02	新規治療用組成物
WO2004006912A2 (en)	2004-01-22	Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
KR20060004959A (ko)	2006-01-16	신장 기능 저하를 갖는 개별 대상자의 이뇨 작용 개선 방법
JPH02501070A (ja)	1990-04-12	骨一消耗病の治療用医薬の組合せ
ES2210399T3 (es)	2004-07-01	Farmacos para profilaxis/tratamiento de las complicaciones de la diabetes.
KR100851938B1 (ko)	2008-08-12	방광 질환의 치료를 위한 카프-오피에이트 작용제
US20040019054A1 (en)	2004-01-29	Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib
US7888341B2 (en)	2011-02-15	Combination of glivec (STI571) with a cyclin-dependent kinase inhibitor, especially flavopiridol, in the treatment of cancer
TWI423800B (zh)	2014-01-21	４－環丙基甲氧基－ｎ－（３，５－二氯－１－氧離子基吡啶－４－基）－５－（甲氧基）吡啶－２－甲醯胺於製備用於治療顱部創傷的藥物之用途
JPH05310573A (ja)	1993-11-22	リウマチ治療薬
JP2003513888A (ja)	2003-04-15	神経疾患治療用医薬品
JP2001525839A (ja)	2001-12-11	炭素環式ヌクレオシド１５９２ｕ８９を含有する抗ウイルス的組合せ
JP2007518768A (ja)	2007-07-12	有機化合物の組み合わせ物
JP2003171266A (ja)	2003-06-17	キシリトールを含有する解熱性調剤
TW201946619A (zh)	2019-12-16	治療神經性病變疼痛之方法
JPH04501563A (ja)	1992-03-19	水溶性イボパミン酸付加塩を含有する眼薬